First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial

Although patients with microsatellite instable metastatic colorectal cancer (CRC) benefit from immune checkpoint blockade, chemotherapy with targeted therapies remains the only therapeutic option for microsatellite stable (MSS) tumors. The single-arm, phase 1b/2 MEDITREME trial evaluated the safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Thibaudin, Marion, Fumet, Jean-David, Chibaudel, Benoist, Bennouna, Jaafar, Borg, Christophe, Martin-Babau, Jerome, Cohen, Romain, Fonck, Marianne, Taieb, Julien, Limagne, Emeric, Blanc, Julie, Ballot, Elise, Hampe, Léa, Bon, Marjorie, Daumoine, Susy, Peroz, Morgane, Mananet, Hugo, Derangère, Valentin, Boidot, Romain, Michaud, Henri-Alexandre, Laheurte, Caroline, Adotevi, Olivier, Bertaut, Aurélie, Truntzer, Caroline, Ghiringhelli, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427431/
https://www.ncbi.nlm.nih.gov/pubmed/37563240
http://dx.doi.org/10.1038/s41591-023-02497-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427431/
https://www.ncbi.nlm.nih.gov/pubmed/37563240
http://dx.doi.org/10.1038/s41591-023-02497-z

Ejemplares similares